PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Correlation of Pyruvate Kinase M2 Expression with Clinicopathological Data in Ovarian Cancer.

Abstract It has been shown in many studies that expression of pyruvate kinase (PK) enzyme plays a key role during cellular metabolism. There is evidence that cancer cells manifesting very dynamic proliferation may control their division in various mechanisms, i.a. by expression of PKM2 isoform. The exact role of PKM2 in ovarian cancer (OC) cells and cancer associated fibroblasts (CAFs) have not been elucidated.
PMID
Related Publications

PKM2, cancer metabolism, and the road ahead.

The lack of evidence for correlation of pyruvate kinase M2 expression with tumor grade in non-small cell lung cancer.

Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer.

Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism.

Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread.

Authors

Mayor MeshTerms
Keywords

Pyruvate kinase

immunohistochemistry

ovarian cancer

Journal Title anticancer research
Publication Year Start




PMID- 29277786
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20180105
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Correlation of Pyruvate Kinase M2 Expression with Clinicopathological Data in
      Ovarian Cancer.
PG  - 295-300
AB  - BACKGROUND/AIM: It has been shown in many studies that expression of pyruvate
      kinase (PK) enzyme plays a key role during cellular metabolism. There is evidence
      that cancer cells manifesting very dynamic proliferation may control their
      division in various mechanisms, i.a. by expression of PKM2 isoform. The exact
      role of PKM2 in ovarian cancer (OC) cells and cancer associated fibroblasts
      (CAFs) have not been elucidated. MATERIALS AND METHODS: The present study was
      focused on analysis of PKM2 expression in cancer cells and CAFs in 97 OC cases,
      mostly of serous histological type. Moreover, relationships between expression of
      PKM2 and proliferation (Ki-67; MCM-2, -3, -7; cyclin D1), vascular (CD31, D2-40) 
      and mesenchymal (Vim and alphaSMA) markers as well as receptors (ER, PR, HER2,
      EGFR) were examined. All observations were evaluated in regard to available
      clinicopathological data. RESULTS: The expression of PKM2 was disclosed only in
      cytoplasm of OC cells. No statistically significant correlation between PKM2 and 
      tested markers was found. In regard to available clinicopathological data only an
      increasing trend of PKM2 expression with increasing grade of histological
      malignancy G was found (p=0.07). CONCLUSION: Due to achieved results concerning
      expression of PKM2 there is a lack of evidence for its diagnostic and prognostic 
      usage in OC.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kobierzycki, Christopher
AU  - Kobierzycki C
AD  - Department of Human Morphology and Embryology, Wroclaw Medical University,
      Wroclaw, Poland [email protected]
FAU - Piotrowska, Aleksandra
AU  - Piotrowska A
AD  - Department of Human Morphology and Embryology, Wroclaw Medical University,
      Wroclaw, Poland.
FAU - Latkowski, Krzysztof
AU  - Latkowski K
AD  - Department of Gynecology and Obstetrics, Wroclaw Medical University, Wroclaw,
      Poland.
FAU - Zabel, Maciej
AU  - Zabel M
AD  - Department of Human Morphology and Embryology, Wroclaw Medical University,
      Wroclaw, Poland.
AD  - Department of Histology and Embryology, University of Medical Sciences, Poznan,
      Poland.
FAU - Nowak-Markwitz, Ewa
AU  - Nowak-Markwitz E
AD  - Department of Gynecologic Oncology, University of Medical Sciences, Poznan,
      Poland.
FAU - Spaczynski, Marek
AU  - Spaczynski M
AD  - Department of Gynecologic Oncology, University of Medical Sciences, Poznan,
      Poland.
FAU - Kedzia, Witold
AU  - Kedzia W
AD  - Department of Gynecology, University of Medical Sciences, Poznan, Poland.
FAU - Pula, Bartosz
AU  - Pula B
AD  - Department of Human Morphology and Embryology, Wroclaw Medical University,
      Wroclaw, Poland.
FAU - Podhorska-Okolow, Marzenna
AU  - Podhorska-Okolow M
AD  - Department of Human Morphology and Embryology, Wroclaw Medical University,
      Wroclaw, Poland.
FAU - Dziegiel, Piotr
AU  - Dziegiel P
AD  - Department of Human Morphology and Embryology, Wroclaw Medical University,
      Wroclaw, Poland.
AD  - Department of Physiotherapy, University School of Physical Education, Wroclaw,
      Poland.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Carrier Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (Thyroid Hormones)
RN  - 0 (thyroid hormone-binding proteins)
SB  - IM
MH  - Carrier Proteins/*metabolism
MH  - Cytoplasm/metabolism
MH  - Female
MH  - Fibroblasts/metabolism
MH  - Humans
MH  - Membrane Proteins/*metabolism
MH  - Middle Aged
MH  - Ovarian Neoplasms/*metabolism
MH  - Thyroid Hormones/*metabolism
OTO - NOTNLM
OT  - *Pyruvate kinase
OT  - *immunohistochemistry
OT  - *ovarian cancer
EDAT- 2017/12/27 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/11/13 00:00 [received]
PHST- 2017/11/25 00:00 [revised]
PHST- 2017/11/27 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 38/1/295 [pii]
AID - 10.21873/anticanres.12221 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):295-300. doi: 10.21873/anticanres.12221.